Related references
Note: Only part of the references are listed.NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Alexander Drilon et al.
CANCER DISCOVERY (2023)
CCN2 Increases TGF-β Receptor Type II Expression in Vascular Smooth Muscle Cells: Essential Role of CCN2 in the TGF-β Pathway Regulation
Antonio Tejera-Munoz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors
Clare Keddy et al.
MOLECULAR CANCER THERAPEUTICS (2022)
The reactome pathway knowledgebase 2022
Marc Gillespie et al.
NUCLEIC ACIDS RESEARCH (2022)
Hallmarks of Cancer: New Dimensions
Douglas Hanahan
CANCER DISCOVERY (2022)
TGFβ biology in cancer progression and immunotherapy
Rik Derynck et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
ROS1-dependent cancers - biology, diagnostics and therapeutics
Alexander Drilon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Genomic Characterization of de novo Metastatic Breast Cancer
Ana C. Garrido-Castro et al.
CLINICAL CANCER RESEARCH (2021)
Analyzing causal relationships in proteomic profiles using CausalPath
Augustin Luna et al.
STAR PROTOCOLS (2021)
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon et al.
LANCET ONCOLOGY (2020)
Mechanisms and therapeutic implications of hypermutation in gliomas
Mehdi Touat et al.
NATURE (2020)
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
Romel Somwar et al.
COMMUNICATIONS BIOLOGY (2020)
Defining a new nomenclature for the structures of active and inactive kinases
Vivek Modi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update)
Uku Raudvere et al.
NUCLEIC ACIDS RESEARCH (2019)
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
Lorenza Landi et al.
CLINICAL CANCER RESEARCH (2019)
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins
Dana S. Neel et al.
CANCER RESEARCH (2019)
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Francisco Sanchez-Vega et al.
CELL (2018)
Mechanisms of receptor tyrosine kinase activation in cancer
Zhenfang Du et al.
MOLECULAR CANCER (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
Carman K. M. Ip et al.
NATURE COMMUNICATIONS (2018)
Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma
Monika A. Davare et al.
CLINICAL CANCER RESEARCH (2018)
Role of the CCN protein family in cancer
Hyungjoo Kim et al.
BMB REPORTS (2018)
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Recent Advances in Targeting ROS1 in Lung Cancer
Jessica J. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
Alison M. Schram et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
The KSEA App: a web-based tool for kinase activity inference from quantitative phosphoproteomics
Danica D. Wiredja et al.
BIOINFORMATICS (2017)
Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies
Yael P. Mosse
CLINICAL CANCER RESEARCH (2016)
SIFT missense predictions for genomes
Robert Vaser et al.
NATURE PROTOCOLS (2016)
Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency
Maki Inoue et al.
CARCINOGENESIS (2016)
The kinome 'at large' in cancer
Emmy D. G. Fleuren et al.
NATURE REVIEWS CANCER (2016)
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
Helen Y. Zou et al.
CANCER CELL (2015)
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors
Monika A. Davare et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
PhosphoSitePlus, 2014: mutations, PTMs and recalibrations
Peter V. Hornbeck et al.
NUCLEIC ACIDS RESEARCH (2015)
Automatic Identification of Mobile and Rigid Substructures in Molecular Dynamics Simulations and Fractional Structural Fluctuation Analysis
Leandro Martinez
PLOS ONE (2015)
Evol and ProDy for bridging protein sequence evolution and structural dynamics
Ahmet Bakan et al.
BIOINFORMATICS (2014)
ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
Scott C. Bresler et al.
CANCER CELL (2014)
KinomeXplorer: an integrated platform for kinome biology studies
Heiko Horn et al.
NATURE METHODS (2014)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Receptor Tyrosine Kinases: Legacy of the First Two Decades
Joseph Schlessinger
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
The Soft Agar Colony Formation Assay
Stanley Borowicz et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2014)
Mouse Model for ROS1-Rearranged Lung Cancer
Yasuhito Arai et al.
PLOS ONE (2013)
Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target
Anna Saborowski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer
Monica Red Brewer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
Monika A. Davare et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells
Pedro Casado et al.
SCIENCE SIGNALING (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies
Sandrine Medves et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
SIFT web server: predicting effects of amino acid substitutions on proteins
Ngak-Leng Sim et al.
NUCLEIC ACIDS RESEARCH (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
CCN1 and CCN2: blood brothers in angiogenic action
Lester F. Lau
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2012)
ProDy: Protein Dynamics Inferred from Theory and Experiments
Ahmet Bakan et al.
BIOINFORMATICS (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis
Inamul Haque et al.
MOLECULAR CANCER (2011)
Predicting the functional impact of protein mutations: application to cancer genomics
Boris Reva et al.
NUCLEIC ACIDS RESEARCH (2011)
CCN2 Is Required for the TGF-β Induced Activation of Smad1-Erk1/2 Signaling Network
Sashidhar S. Nakerakanti et al.
PLOS ONE (2011)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Kinase mutations in human disease: interpreting genotype-phenotype relationships
Piya Lahiry et al.
NATURE REVIEWS GENETICS (2010)
Pathogenic or Not? And If So, Then How? Studying the Effects of Missense Mutations Using Bioinformatics Methods
Janita Thusberg et al.
HUMAN MUTATION (2009)
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Rani E. George et al.
NATURE (2008)
HER2 status and benefit from adjuvant trastuzumab in breast cancer
Soonmyung Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
Determinants of protein function revealed by combinatorial entropy optimization
Boris Reva et al.
GENOME BIOLOGY (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells
SJ Isakoff et al.
CANCER RESEARCH (2005)
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures
J Debnath et al.
METHODS (2003)
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme
JS Smith et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Share Paper
